Browsing: losses

Former Group Chief Executive Officer of the Nigerian National Petroleum Company Limited (NNPCL), Mele Kyari, has denied allegations that ₦210 trillion was missing from the company’s accounts, insisting that the disputed figures represent accounting entries rather than financial losses.

Energy Fuels Inc.UUUU reported a loss of 20 cents per share in the third quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 10 cents. UUUU had reported a loss of 7 cents in the year-ago quarter. Non-cash investment losses and acquisition-related expenses weighed on profitability.

AppLovin APP, Clarivate CLVT, Nextpower NXT, Magnite MGNI, and Grab Holdings GRAB were the top performers among US-listed stocks covered by Morningstar analysts.

Anthropic’s quarterly revenue swelled to $17 billion but it still posted a net loss for the latest three months, the artificial intelligence giant said in an updated IPO filing released on Monday.

Investor enthusiasm for artificial intelligence’s potential to transform the global economy has fueled massive bets on the sector; however, growing concerns about a possible downturn are prompting investors to seek financial protection against losses, The Wall Street Journal reported Saturday.

Ever-growing cashback limits, high returns on cash balances, massive discounts on some purchases: crypto-backed payment cards are offering rewards that seem nearly impossible to match.

Binance, the world’s largest cryptocurrency exchange, says it has covered 90% of the $6.3bn (£4.7bn) assets stolen in a hack on Thursday.

Scatec just dropped its Q3 2026 report into a market that had already been cooling on the story, with the share price down roughly 18% over the past month and closing at NOK84.65 on the day of the release. The headline is stark. Revenue reached NOK1.68b for the quarter, yet the company booked a heavy…

Company says remaining 10% consisted of lower-liquidity tokens 01 November 2026•Update: 01 November 2026 ISTANBUL

Moderna (MRNA) extended losses on Friday following a sharp sell-off in the previous session, as investors digested data from a late-stage trial of its personalized melanoma vaccine.